Holen Sie sich die Stockscreener-App
0.00
100.00%
-3.65
Schlusskurs vom Vortag:
$3.65
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$378.94M
Einnahmen:
$234.04M
Nettoeinkommen (Verlust:
$-323.92M
KGV:
0.00
EPS:
-3.8
Netto-Cashflow:
$-223.46M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$6.65
Revance Therapeutics Inc Stock (RVNC) Company Profile
Firmenname
Revance Therapeutics Inc
Sektor
Branche
Telefon
(615) 724-7755
Adresse
1222 DEMONBREUN STREET, NASHVILLE, CA
Vergleichen Sie RVNC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RVNC
Revance Therapeutics Inc
|
0.00 | 378.94M | 234.04M | -323.92M | -223.46M | -3.80 |
|
ONC
Beigene Ltd Adr
|
236.86 | 24.29B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.18 | 110.94B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2996 | 45.05M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
614.79 | 61.99B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.73 | 5.75B | 0 | -153.72M | -103.81M | -2.00 |
Revance Therapeutics Inc Stock (RVNC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-01-29 | Herabstufung | Mizuho | Buy → Neutral |
| 2024-01-09 | Herabstufung | Goldman | Buy → Neutral |
| 2023-08-16 | Hochstufung | Exane BNP Paribas | Underperform → Neutral |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-09-22 | Eingeleitet | Goldman | Buy |
| 2021-10-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-10-15 | Bestätigt | Needham | Buy |
| 2020-08-11 | Fortgesetzt | Mizuho | Buy |
| 2020-03-23 | Herabstufung | Goldman | Buy → Neutral |
| 2019-12-02 | Eingeleitet | Goldman | Buy |
| 2019-10-30 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2019-06-11 | Eingeleitet | Barclays | Overweight |
| 2019-02-15 | Eingeleitet | Wells Fargo | Market Perform |
| 2019-02-14 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-01-29 | Eingeleitet | Stifel | Buy |
| 2018-11-16 | Hochstufung | Guggenheim | Neutral → Buy |
| 2018-09-17 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-04-20 | Bestätigt | Mizuho | Buy |
| 2018-03-27 | Eingeleitet | Needham | Buy |
| 2018-03-05 | Eingeleitet | Goldman | Buy |
| 2018-01-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2017-12-06 | Eingeleitet | Guggenheim | Buy |
| 2017-12-06 | Bestätigt | Mizuho | Buy |
| 2017-11-27 | Eingeleitet | Barclays | Overweight |
| 2017-11-17 | Eingeleitet | Mizuho | Buy |
| 2017-08-22 | Eingeleitet | JMP Securities | Mkt Outperform |
Alle ansehen
Revance Therapeutics Inc Aktie (RVNC) Neueste Nachrichten
Price T Rowe Associates Inc. MD Purchases 7,839 Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results - ACCESS Newswire
Dermata Therapeutics, Inc. SEC 10-Q Report - TradingView
Revance Therapeutics (NASDAQ:RVNC) Now Covered by StockNews.com - Defense World
Hsbc Holdings PLC Cuts Stock Holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Lost Money on Revance Therapeutics, Inc. (RVNC)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
Shareholders that Lost Money on Revance Therapeutics, Inc. (RVNC) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Revance Therapeutics, Inc. Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information - ACCESS Newswire
Revance Therapeutics, Inc. (NASDAQ:RVNC) Shares Acquired by Wells Fargo & Company MN - Defense World
Revance Therapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationRVNC - ACCESS Newswire
MetLife Investment Management LLC Has $184,000 Stock Position in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Analysts Set Revance Therapeutics, Inc. (NASDAQ:RVNC) PT at $8.39 - Defense World
Invesco Ltd. Boosts Holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Revance Therapeutics (NASDAQ:RVNC) Earns Hold Rating from Analysts at StockNews.com - Defense World
Spasticity Market Predicted to See Upsurge Through 2032, Highlights DelveInsight | Jazz Pharmaceuticals, Revance Therapeutics, Ipsen - Barchart.com
Press Release Distribution & PR Platform - ACCESS Newswire
Revance Therapeutics, Inc. (NASDAQ:RVNC) Shares Sold by LPL Financial LLC - Defense World
Revance Announces Blue Lizard® Australian Sunscreen Named the #1 Selling Mineral Sunscreen Brand - Longview News-Journal
Revance Therapeutics (NASDAQ:RVNC) Coverage Initiated at StockNews.com - Defense World
Geode Capital Management LLC Raises Position in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Investigation announced for Long-Term Investors in Revance - openPR.com
Who’s Hired? Botox Biosimilar Developer Aeon Takes CEO From Rival Revance - insights.citeline.com
JPMorgan Chase & Co. Sells 2,335,359 Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Former Revance Therapeutics Leader Takes AEON Helm: Inside the Race to Challenge BOTOX's $3B Market - Stock Titan
Revance Therapeutics, Inc. (NASDAQ:RVNC) Shares Sold by Vanguard Group Inc. - Defense World
Corebridge Financial Inc. Reduces Holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Wellington Management Group LLP Trims Position in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Norges Bank Takes Position in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
KLP Kapitalforvaltning AS Takes Position in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Commonwealth Equity Services LLC Cuts Holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Revance Therapeutics, Inc. (NASDAQ:RVNC) Receives Average Recommendation of “Hold” from Analysts - Defense World
StockNews.com Initiates Coverage on Revance Therapeutics (NASDAQ:RVNC) - Defense World
BIOJUVE® Honoured as Best Cosmetics of the Year at AMWC 2025 in Monaco - The Malaysian Reserve
Public market insider buying at Prime Mining (PRYM) - The Globe and Mail
RVNC INVESTIGATION: Hagens Berman Encourages Revance Therapeutics (RVNC) Investors with Significant Losses to Contact Firm’s Attorneys Now, Firm Investigating Possible Securities Law Violations - ACCESS Newswire
RVNC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Revance Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Bay Area drug veteran heads New Zealand company's oral ketamine spinoff targeting depression - The Business Journals
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Revance Therapeutics, Inc. a Class Action Lawsuit and a Lead Plaintiff Deadline of February 8, 2022RVNC - ACCESS Newswire
Crown Laboratories rebrands as Revance following acquisition - MSN
Finanzdaten der Revance Therapeutics Inc-Aktie (RVNC)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.33%
1.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):